Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma 1

Interventions

Cyclophosphamide 35fludarabine 18Methotrexate 17fludarabine phosphate 16Dexamethasone 16blinatumomab 15Vincristine 15Cytarabine 14Melphalan 12Tacrolimus 11Etoposide 11pegaspargase 10Whole-Body Irradiation 9Mercaptopurine 9Calcium Dobesilate 9merphos 8Dasatinib 8Busulfan 8Asparaginase 8Thiotepa 7Prednisone 7Mycophenolic Acid 7Leucovorin 7Granulocyte Colony-Stimulating Factor 7Doxorubicin 7prednylidene 6ponatinib 6calaspargase pegol 6Stem Cell Transplantation 6Specimen Handling 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Precursor Cell Lymphoblastic Leukemia-Lymphoma × Biological Products × Clear all
NCT01430390 2025-06-11

In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies

Memorial Sloan Kettering Cancer Center

Phase 1 Active not recruiting
19 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡